Eli Lilly to Present Landmark monarchE Overall Survival Data for Verzenio in High-Risk Early Breast Cancer at 2025 ESMO Annual Meeting
Eli Lilly and Company will present new data from its oncology portfolio at the 2025 ESMO Annual Meeting in Berlin, scheduled for October 17-21. Key presentations include the primary overall survival analysis from the Phase 3 monarchE study of Verzenio in high-risk early breast cancer, along with updated results from therapies targeting various cancers. These results have not yet been released.
Eli Lilly and Company announced that new data from its oncology portfolio and pipeline will be presented at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Meeting, scheduled for October 17-21 in Berlin, Germany. Presentations will include the primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer, as well as updated safety and efficacy results from investigational therapies targeting FRα positive ovarian cancer, KRAS G12C-mutant lung cancer, FGFR3-altered bladder cancer, and PIK3CA-mutant advanced breast cancer. Results from these studies will be presented at the ESMO meeting and have not yet been released. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE95319) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
